These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18256859)

  • 1. Established and potential therapeutic applications of octreotide in palliative care.
    Prommer EE
    Support Care Cancer; 2008 Oct; 16(10):1117-23. PubMed ID: 18256859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide therapy in carcinoid disease.
    Bax ND; Woods HF; Batchelor A; Jennings M
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():17-22. PubMed ID: 8822081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of octreotide to manage symptoms of bronchorrhea: a case report.
    Pahuja M; Shepherd RW; Lyckholm LJ
    J Pain Symptom Manage; 2014 Apr; 47(4):814-8. PubMed ID: 24035070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The palliative effects of octreotide in cancer patients.
    Dean A
    Chemotherapy; 2001; 47 Suppl 2():54-61. PubMed ID: 11275702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The therapeutic applications of octreotide].
    Carrera-Hueso FJ; Carrera-Hueso JA; Llorente I
    Med Clin (Barc); 1996 Apr; 106(13):505-16. PubMed ID: 8992134
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term follow-up of two patients with metastatic neuroendocrine tumours treated with octreotide.
    van de Loosdrecht AA; van Bodegraven AA; Sepers JM; Sindram JW
    Neth J Med; 1998 Sep; 53(3):118-23. PubMed ID: 9803143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The palliative effects of octreotide in malignant disease.
    Dean A; Bridge D; Lickiss JN
    Ann Acad Med Singap; 1994 Mar; 23(2):212-5. PubMed ID: 7521613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide.
    Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ
    N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003
    [No Abstract]   [Full Text] [Related]  

  • 10. Octreotide in malignant intestinal obstruction.
    Pandha HS; Waxman J
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():5-10. PubMed ID: 8822079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoid tumours.
    Janmohamed S; Bloom SR
    Postgrad Med J; 1997 Apr; 73(858):207-14. PubMed ID: 9156122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute liver injury and octreotide.
    González-Martín JA; Donnay S; Morillas J; Gómez-Aparicio C; Garcia-Cano J; Pérez-Vigara G; Roldán A
    Am J Gastroenterol; 1996 Nov; 91(11):2434-5. PubMed ID: 8931436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors.
    Trendle MC; Moertel CG; Kvols LK
    Cancer; 1997 Feb; 79(4):830-4. PubMed ID: 9024721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide in pediatric patients.
    Heikenen JB; Pohl JF; Werlin SL; Bucuvalas JC
    J Pediatr Gastroenterol Nutr; 2002 Nov; 35(5):600-9. PubMed ID: 12454572
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroendocrine tumours - Medical therapy: Biological.
    Rinke A; Krug S
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):79-91. PubMed ID: 26971845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide LAR in carcinoid: how to dose?
    Yao JC; Kvols LK
    Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
    [No Abstract]   [Full Text] [Related]  

  • 17. Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire.
    Pistevou-Gombaki K; Eleftheriadis N; Plataniotis GA; Sofroniadis I; Kouloulias VE
    Palliat Med; 2003 Apr; 17(3):257-62. PubMed ID: 12725479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Somatostatin analogue (octreotide)].
    Sano K; Makuuchi M
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():674-7. PubMed ID: 11762035
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
    Tomassetti P; Migliori M; Corinaldesi R; Gullo L
    Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogs and prednisone in advanced refractory thymic tumors.
    Palmieri G; Montella L; Martignetti A; Muto P; Di Vizio D; De Chiara A; Lastoria S
    Cancer; 2002 Mar; 94(5):1414-20. PubMed ID: 11920496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.